Risks and benefits from CDK inhibitors for advanced HR+ Her 2-breast cancer-MedSci.cn

Risks and benefits from CDK inhibitors for advanced HR+ Her 2-breast cancer

Messina, C; Messina, M; Zanardi, E

Messina, C (reprint author), Policlin Hosp San Martino IST, Acad Unit Med Oncol, Genoa, Italy.; Messina, C (reprint author), Univ Genoa, Sch Med, Dept Internal Med, Genoa, Italy.

ANNALS OF ONCOLOGY, 2017; 28 (12): 3099

科室
- - 订阅+
  - 更多科室
工具
服务